In consideration of the enormous potential of GFRAL modulators to counteract overeating and obesity, the GDF-15/GFRAL/RET pathway is the most active area for drug development in this endeavor. This evidence concerns the gene GDF15 and obesity due to melanocortin 4 receptor deficiency.